±MÃD°Q½×11¡G³J¥ÕÃĪ«ªº¶}µo¤Î·s¶i®i

µ{¡@§Ç¡@ªí

S11-4
Development of a light chain-bridged bispecific antibody construct potentially used
for treatment of solid tumours
®}±y²`
°]¹Îªk¤H¥Íª«§Þ³N¶}µo¤¤¤ß¥Íª«»sÃĬã¨s©Ò

¡@¡@Á{§ÉªºÃÒ¾ÚÅã¥Ü¦h¼Ð¹vªº§ÜÅé²Õ¦XªvÀø®ÄªG¸û¦n¡A¥ç¥i­°§C§ÜÃĩʪº²£¥Í(¨Ò¦p:Pertuzumab©Mtrastuzumab¦X¨Ö¨Ï¥Î©óªvÀøHer2¹L«×ªí²{ªº¨ÅÀù¯f¤H)¡A¦pªG³æ¤@§ÜÅé¯à¦P®É¨ã³Æ°w¹ï¯e¯fµo¥Íªº¨â­Ó©Î§ó¦h¼Ð¹v±N¥i¥H¨Ï§ÜÅé§ó¦³®Ä©M¸gÀÙ¶i¦Ó­°§CªvÀø¦¨¥»¡A¥t¤@¤è­±¥ç¥i¥H±a¨Ó·sªºÀ³¥Î»PªvÀø¤è¦¡¡A©Ò¥HÂù¯S²§©Ê§ÜÅé©Î¦h¯S²§©Ê§ÜÅé¦bÂåÃĪºÀ³¥Î¶}µo´NÅ㪺¦³»Ý­n¡C¥Í§Þ¤¤¤ß¦b¹L¥h´X¦~¶}µo¤@­Ó§Q¥Î§ÜÅé»´Ãì(kappa or lambda)¾ô±µªº·s³æÃìÂù¯S²§©Ê§ÜÅéºc§Î¡A¦¹§ÜÅéºc§Î¬°Fab-like¦ý¬°³æ¤@Ð`?Ãì©Ò²Õ¦¨¡A¦]¬°¦³§ÜÅé»´Ã쪺¾ô±µ¨Ïªººc§Î«Üí©w¡A²£¶q«ÜÅãµÛ¸û¨S¦³kappa©Îlambda domain¾ô±µªº³æÃìÂù¯S²§©Ê§ÜÅé°ª¡A¯Â¤Æ¥ç®e©ö¡C¦]¬°¦¹§ÜÅéºc§Î¤À¤l¸û¤p«Ü¾A¦XÀ³¥Î©ó¶}µo»Ý­n¬ï³z¯à¤O¸û¦nªºªvÀø©TºA¸~½F§ÜÅé¡C§Q¥Î¦¹ºc§Î¡A§Ú­Ì¤w¶}µo¤@­Ó»´Ãì¾ô±µªº³æÃìanti-her2/anti-CD3Âù¯S²§©Ê§ÜÅé¡A¦¹§ÜÅé¤À¤lÁäµ²¨ì¸~½F²Ó­M¤Wªºher2©ÎT²Ó­M¤WªºCD3ªº¿Ë©M¤O³£¬ù¦bnM¡A¨ä­n¦³her2+¼Ð¹v¸~½F²Ó­M¦s¦b¤U¤~¯àÅãµÛ¬¡¤Æ±q¦å²G(PBMC)¤ÀÂ÷¨ÓªºT²Ó­M¡A¦¹Âù¯S²§©Ê§ÜÅé¯à¦³®Ä´C¤¶T²Ó­M¹ïher2+¼Ð¹v¸~½F²Ó­Mªº¬r±þ¥]¬Aher2ªí²{§Cªº¸~½F²Ó­M¡A¦b§Q¥ÎNOD/SCID¦Ñ¹«©Ò«Ø¥ßªº²§ºØ²¾´Ó¸~½F°Êª«¼Ò«¬ªºªvÀø¸ÕÅçùØÃҹ껴Ãì¾ô±µªº³æÃìanti-her2/anti-CD3Âù¯S²§©Ê§ÜÅé¯à¸ûtrastuzumab¦³®Ä§í¨îher2+¸~½Fªº¥Íªø¡C